Stay updated on Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Sign up to get notified when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Version history shows a new revision v3.6.0 replacing v3.5.5. A note has been added stating the study is no longer looking for participants.
    Difference
    0.2%
    Check dated 2026-06-12T14:50:30.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer now shows Revision: v3.5.5, replacing Revision: v3.5.4, indicating a new site release.
    Difference
    0.0%
    Check dated 2026-06-05T09:53:06.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The record history now shows Revision: v3.5.4 added, replacing the previous v3.5.3 to reflect a new release tag.
    Difference
    0.0%
    Check dated 2026-05-15T03:04:59.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page’s display revision was updated from v3.5.2 to v3.5.3, reflecting a site/version update rather than any modification to the clinical trial record itself.
    Difference
    0.0%
    Check dated 2026-04-23T21:57:05.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.5.2, replacing the previous Revision: v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-16T12:36:11.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    Added Revision: v3.5.0 and removed Revision: v3.4.3 from the study record history.
    Difference
    0.0%
    Check dated 2026-03-18T23:01:15.000Z thumbnail image

Stay in the know with updates to Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.